US3017415A - Certain benzimidazoles carrying thiazolyl, thiadiazolyl and isothiazolyl substituents in the 2 position - Google Patents

Certain benzimidazoles carrying thiazolyl, thiadiazolyl and isothiazolyl substituents in the 2 position Download PDF

Info

Publication number
US3017415A
US3017415A US2856A US285660A US3017415A US 3017415 A US3017415 A US 3017415A US 2856 A US2856 A US 2856A US 285660 A US285660 A US 285660A US 3017415 A US3017415 A US 3017415A
Authority
US
United States
Prior art keywords
benzimidazole
thiazolyl
acid
thiadiazolyl
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US2856A
Inventor
Lewis H Sarett
Horace D Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BE599143D priority Critical patent/BE599143A/xx
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to US2856A priority patent/US3017415A/en
Priority to US15518A priority patent/US3055907A/en
Priority to DEM45481A priority patent/DE1235321B/en
Priority to GB20378/60A priority patent/GB948635A/en
Priority to ES0263822A priority patent/ES263822A1/en
Priority to FR849060A priority patent/FR1423609A/en
Priority to CH1531565A priority patent/CH423790A/en
Priority to DK19761AA priority patent/DK107167C/en
Priority to CH1531665A priority patent/CH423791A/en
Priority to CH1531865A priority patent/CH423793A/en
Priority to SE436/61A priority patent/SE310883B/xx
Priority to CH1531765A priority patent/CH423792A/en
Priority to CH49061A priority patent/CH423789A/en
Application granted granted Critical
Publication of US3017415A publication Critical patent/US3017415A/en
Priority to OA51102A priority patent/OA00999A/en
Priority to CY30965A priority patent/CY309A/en
Priority to MY196575A priority patent/MY6500075A/en
Priority to SE11797/67A priority patent/SE320977B/xx
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • This invention relates to new compounds useful against helminthiasis. It relates generally to new derivatives of benzimidazole. More particularly, it relates to benzimidazoles having at the 2 position a heterocyclic radical containing nitrogen and sulfur. It is concerned also with methods of making such compounds.
  • the infection known as helminthiasis involves infestation of the animal body, and particularly the gastrointestinal tract, with various species of parasitic worms. It is a very widespread and serious disease, and the methods heretofore available for its treatment and prevention have not been entirely satisfactory. It is an object of this invention to provide a group of substituted benzimidazoles which are effective in controlling helminthiasis, and which lack many of the objectionable features of the known anthelmintics.
  • benzimidazoles having at the 2 position of the benzimidazole ring nucleus a heterocyclic radical containing nitrogen and sulfur possess a significant degree of anthelmintic activity and may be effectively employed in the treatment and/or prevention of helm-inthiasis. It is one object of the invention to provide such compounds. It is a more particular object to provide benzimidazoles substituted at the 2 position with a five-membered heterocyclic radical containing nitrogen and sulfur. A further object is provision of methods of synthesizing such compounds. Still other objects will become apparent from the following description of the invention.
  • the new compounds of our invention have the general structural formula wherein R is a five-membered heterocyclic radical containing nitrogen and sulfur and R is hydrogen, a lower alkyl or a lower alkenyl radical.
  • R is a five-membered heterocyclic radical containing nitrogen and sulfur and R is hydrogen, a lower alkyl or a lower alkenyl radical.
  • the invention also includes within its scope acid addition salts of these benzimidazoles.
  • the five-membered heterocyclic radical (R in the above formula), which is attached to the benzimidazole at one of its carbon atoms, may be a thiazolyl, isothiazolyl or thiadiazolyl radical.
  • R is a thiazolylor isothiazolyl moiety
  • the point of attachment to the benzimidazole nucleus may be at any one of the three carbon atoms of the heterocyclic ring, as indicated by the broken lines in the partial structures:
  • R is a thiadiazolyl group containing two nitrogen atoms and one sulfur atom in the ring
  • the radical may be attached to the benzimidazole at either of the two carbon atoms in a 1,2,3-thiadiazle or a 1,2,4-thiadiazole:
  • N la is
  • the heterocyclic radical may, if desired, be further substituted at a carbon atom with a lower hydrocarbon group such as a lower alkyl radical, the only limitation in this regard being that imposed by the availability of the substituted thiazoles, isothiazoles or thiadiazoles to be used as starting materials.
  • 2-(2-thiazolyl)-benzimidazoles having a lower alkyl group at the 4 position of the thiazole ring and the 2-(5-isothiazolyl)-benzimidazoles having a lower alkyl group at the 3 position of the isothiazole ring such as 2-(4-methyl-2'-thiazolyl) benzimidazole and 2-(3-methyl-5'-isothiazolyl)-benzimidazole are illustrative of this aspect of the invention.
  • the N-l position of the benzimidazoles may be substituted with hydrogen, a lower alkyl group such as methyl, ethyl, propyl or isopropyl, or a lower alkenyl radical of the type represented by allyl and methallyl.
  • the alkyl and alkenyl radicals preferably contain less than six carbon atoms.
  • the six-membered ring of the benzimidazole nucleus may also be substituted, as with lower alkyl groups at the 5 and/ or 6 positions.
  • Methyl groups are the preferred substituents although ethyl, propyl and similar lower alkyl radicals may, of course, be employed.
  • the so-called pseudo-alkyl radicals such as a trifluoromethyl substituent, may also be present at the 5 or 6 positions of the benzimidazole.
  • the 2-substituted benzimidazoles described herein are isolated as the free bases by the synthetic processes normally employed. They are readily converted to acid addition salts by treatment with acid. Typical salts which may be formed in this manner are mineral acid salts such as the hydrohalides, e.g.
  • hydrochloride hydrobromide, hydroiodide, sulfates, nitrates, phosphates, and the like, aliphatic acid salts such as the acetate, trimethylacetate, t-butylacetate, or propionate, salts of polycarboxylic acids such as the citrate, oxalate, succinate and the like and salts of other insoluble organic acids such as the embonate and hydroxynaphthoate salts. Certain of these salts are much more water soluble than the free bases. This is true of the hydrohalides.
  • solubility properties of a particular compound may be generally adjusted by judicious selection of a salt.
  • the compounds of this invention are used in salt form as anthelmintics, it is, of course, desirable that the particular acid employed be an edible, non-toxic one.
  • the 2-thiazoly1 benzimidazoles wherein the point of attachment to the benzimidazole moiety is either the 2 or 4 position of the thiazole ring, represent the preferred compounds of the invention.
  • the preparation of these substances and the other Z-substituted benzimidazoles described herein comprises broadly the reaction of thiazolyl, isothiazolyl or thiadiazolyl carboxylic acid or derivative thereof, such as an ester, amide, nitrile acid halide or aldehyde, with a compound of the general formula R NH:
  • Y is -NO NH or -NHR
  • R is lower alkyl or lower alkenyl
  • R and R are hydrogen or lower alkyl (or pseudo-alkyl).
  • the Z-heterocyclic benzimidazoles are prepared by reacting together o-phenylenediamine and a heterocyclic carboxylic acid (or derivative thereof) in polyphosphoric acid.
  • the process is carried out at elevated temperatures, and preferably at temperatures of about 150300 C.
  • the optimum reaction time and temperature will of course, depend to some extent on the particular reactants being employed, but in general good yields of the desired compounds are obtained by conducting the process at temperatures of about 175 to about 275 C. for from 2 to 6 hours.
  • the heterocyclic reactant is one that tends to decompose at elevated temperature, e.g.
  • thiazole-2-carboxamide is preferred over thiazole-Z-carboxylic acid as starting material in the synthesis of 2-(2-thiazoyl)-benzimidazole since the free acid tends to decompose to thiazole itself at reaction temperature.
  • the desired Z-substituted benzimidazoles are recovered by cooling the reaction mixture and diluting it with water. Where the benzimidazoles do not crystallize readily under these conditions, they are precipitated by neutralizing the quenched mixture with a base such as ammonium hydroxide, an alkali metal hydroxide or an alkali metal carbonate.
  • the Z-heterocyclic benzimidazole compounds may be synthesized by reacting together o-phenylene-diamine and an aldehydo heterocyclic compound such as thiazole-4-aldehyde or 1,2,3-thiadiazole-4-aldehyde in a reaction medium comprising nitrobenzene.
  • a 1-alkyl-2- heterocyclic benzimidazole, such as 1-methyl-2[4-(1,2, 3'-thiadiazolyl)]-benzimidazole is produced from N- methyl-o-phenylenediamine. Good results are obtained by heating the reaction mixture slowly to the reflux temperature (ca. 210 C.), and maintaining that temperature for a very short time.
  • a solvent such as a lower alkanol may be used to promote solubility of the reactants at lower temperatures. Such solvents are allowed to distil oil during the heating period.
  • the Z-heterocyclic benzimidazoles are readily recovered. In many cases they crystallize directly on cooling the nitrobenzene solution. Alternatively, they may be crystallized by addition of ether or petroleum ether to the nitrobenzene solution.
  • 2-heterocyclic benzimidazoles are prepared by condensation of a heterocyclic aldehyde with a compound of Formula II above.
  • the reaction is preferably brought about in a suitable solvent such as a lower alkanol, e.g. methanol, ethanol, isopropanol or t-butanol.
  • a suitable solvent such as a lower alkanol, e.g. methanol, ethanol, isopropanol or t-butanol.
  • the first product formed is the Schiff base of the aldehyde and the primary amine. In normal practice this is not isolated but rather converted directly to the benzimidazole.
  • the ring closure of the Schiff base to the 2-heterocyclic benzimidazole is effected with a suitable oxidizing agent such as cupric acetate, lead tetracetate, mercuric acetate, air and the like.
  • an ester or an acid halide derivative of the hetrocycle is employed.
  • An intermediate anilide is formed initially.
  • the nitro group is then reduced and benzimidazole formation effected by treatment of the intermediate anilide with a reducing system such as zinc-hydrochloric acid or zinc-acetic acid.
  • a heavy metal reagent is used to bring about benzimidazole formation from an o-phenylenediamine in the above two processes, an insoluble heavy metal salt of the Z-heterocyclic benzimidazole is formed.
  • This material is readily converted to the free benzimidazole by removal of the heavy metal with reagents suitable for this purpose such as hydrogen sulfide, ammonium polysulfide, ammonium hydroxide and the like.
  • 2-heterocyclic benzimidazoles are prepared by heating a mixture of an o-phenylenediame or an N-alkyl-o-phenylenedi amine and a lower alkyl heterocyclic carboxylate with an aqueous mineral acid such as aqueous sulfuric or phosphoric acid in a closed system, i.e. an autoclave or bomb. The process is conducted at temperatures of from about 180 C. for 3-10 hours, and the 2-hetero cyclic benzimidazole recovered from the acid reaction mixture by application of the isolation and purification techniques described hereinabove.
  • 1-substituted-Z-heterocyclic benzimidazoles where R in Formula. I above is alkyl or alkenyl, may further be synthesized by alkylation or alkenylation of the 2-hetero' cyclic benzimidazole itself.
  • an alkali metal salt of the benzimidazole is reacted with an ester of a strong acid and a lower alkanol or lower alkenol, such as methyl bromide, methyl iodide, allyl bromide and the like, or with an alkyl sulfate such as dimethyl sulfate.
  • the Z-Substituted benzimidazoles described herein have a high degree of anthelmintic activity and are useful in the treatment and/ or prevention of helminthiasis, a parasitic disease which causes widespread and often serious infection in domesticated animals such as swine, ruminants such as cattle and sheep and even in man.
  • the compounds are mixed with a non-toxic edible carrier to form a feed supplement which is then incorporated in the animal feed in the desired concentration, or they may be administered in unit dosage forms which, in the case of large domesticated animals, take the form of boluses, or in the form of a liquid drench.
  • water soluble salts or a dispersable, wettable powder containing the 2-heterocyclic benzimidazole may be added to the drinking water of the animals.
  • EXAMPLE 3 2- [4 (1 ,2 ,3 '-thiadiaz0lyl l-benzimidazole 6.0 g. of 4-carbethoxy-1,2,3-thiadiazole and 8.0 g. of o-phenylenediamine are added to 120 g. of polyphosphoric acid preheated to about 80 C. in a nitrogen atmosphere. After stirring for one hour at 125 C. the temperature is raised to 225 C. for one hour. The brown solution is cooled to about 100 C. and poured (with stirring) in a thin stream into 200 cc. of cold water. A dark green amorphous solid is filtered OE and the filtrate neutralized to pH ca. 7 With sodium hydroxide solution.
  • EXAMPLE 4 2- [3 1 ,2',5 -thiadiazolyl) -benzimidaz0le 12.8 g. (0.081 mole) of 3-carbethoxy-1,2,5-thiadiazole, 11 g. (0.1 mole) of o-phenylenediamine and 50 g. of polyphosphoric acid are mixed and heated with stirring at 175 C. in a nitrogen atmosphere for 3 hours. At this time, the dark solution is cooled to about 100 C. and then slowly poured with stirring into about 500 ml. of cold water. The tacky threads slowly change to a brown solid. The suspension is neutralized to pH ca. 7 to precipitate the remainder of the product.
  • the solid is washed with water, sodium bicarbonate solution to insure neutrality and dried in air.
  • the 2-[3'-(1,2,5'- thiadiazolyl)J-benzimidazole is then recrystallized from ethyl acetate solution with a decolorizing charcoal treatment, M.P. 26870 C. (sublimation 240). Recrystalization from ethyl acetate raises the M.P. to 272 274 C.
  • the hydrobromide salt of this product is prepared by dissolving the product in hot alcoholic hydrogen bromide, treating the hot solution with activated charcoal, removing the charcoal by filtration, and adding about 3 volumes of ether to the alcoholic solution.
  • the hydrobromide salt crystallizes on cooling.
  • EXAMPLE 6 l-methyl-Z-(4-thiaz0lyl)-benzimidaz0le A. To 10 g. of 2-(4-thiazolyl)-benzirnidazole in 100 m1. of dry dimethylformamide is added 2.3 g. of a 52% sodium hydride emulsion in mineral oil. The mixture is stirred at room temperature for about 20 minutes and then warmed carefully to about C. for 10 minutes. It is cooled to room temperature and 7.1 g. of methyl iodide in 10 ml. of dimethylformamide is added slowly to the cooled solution. The reaction mixture is then heated to about 80 C. for 20 minutes, cooled, diluted with 200 ml.
  • the above product is also produced by adding 5 g. of N-methyl-o-phenylenediamine dihydrochloride in 75 ml. of 50% alcohol to a solution of 10 g. of cupric acetate and 6 g. of thiazole-4-aldehyde in 300 ml. of Water. The addition is carried out at about 0 C. and the reaction mixture is then heated in a hot water bath for about 30 minutes.
  • the resulting brown solid is recovered by filtration and washed with cold water and ethanol. It is then suspended in dilute hydrochloric acid and a stream of hydrogen sulfide bubbled slowly through the suspension until it is saturated with hydrogen sulfide. It is filtered and the filtrate obtained after removal of the copper sulfide is concentrated to dryness and the residue dissolved in a small volume of water. The solution is neutralized with potassium carbonate solution and extracted with chloroform. The chloroform extract is concentrated to dryness and the resulting residue extracted with petroleum ether. On concentration of the petroleum ether extracts, to a small volume, 1-methyl-2-(4-thiazolyl) -benzimidazole precipitates.
  • the hydrochloride salt is obtained by treatment of the base with ethanolic hydrogen chloride by the method described in Example 10.
  • EXAMPLE 8 2-(2'-thiaz0lyl) -benzimidazole To 11 g. of o-phenylenediamine in 100 ml. of ethanol is added with stirring 11.3 g. of thiazole-Z-aldehyde in 100 ml. of ethanol. This mixture is stirred for about 1 hour at room temperature after which time 20 g. of cupric acetate monohydrate in 200 ml. of water is added dropwise with rapid stirring. After this addition is completed, the reaction mixture is heated at gentle reflux for about 30 minutes. It is then cooled and the copper salt recovered by filtration and washed with water. It is then suspended in 250 ml. of 95% ethanol and saturated with hydrogen sulfide (with stirring). The insoluble copper sulfide is removed by filtering and the clear filtrate concentrated essentially to dryness. The 2-(2'-thiazolyl)- benzimidazole thus obtained is purified by recrystallization from aqueous ethanol.
  • EXAMPLE 10 A. 5 g. of 2-(2-thiazolyl)-benzimidazole is added with stirring to 100 ml. of ethanol saturated with dry hydrogen chloride. An additional 125 ml. of ethanol is added to give a dark brown solution. The solution is treated with 5 g. of activated charcoal and the charcoal removed by filtration. The clear filtrate is diluted with three times its volume of ethyl ether and the resulting mixture chilled. After a short time, crystals of 2-(2'-thiazolyl)-benzimidazole monohydrochloride appear, M.P. 246 C.
  • EXAMPLE 12 2(4-tlziaz0lyl)-5,6-dimethyl benzimidazole 8 g. of 4-thiazolyl aldehyde in ml. of ethanol is added at room temperature to 10 g. of 4,5-dimethyl-ophenylenediamine in 200 ml. of ethanol. The mixture is stirred for one hour at room'temperature and a solution of 16 g. of cupric acetate in 400 ml. of water is added in small portions.
  • EXAMPLE 15 2-(4-thiaz0lyl) -benzimidaz0le 13 g. of 4-thiazolyl acid chloride and 13 g. of o-nitroaniline are stirred together in 35 ml. of pyridine at room temperature for about 12 hours. At the end of this time, the mixture is quenched in ice water and the solid nitroanilide recovered by filtration and Washed with dilute sodium carbonate solution. The solid is suspended in ml. of glacial acetic acid, and 80 ml. of o-N-hydrochloric acid added to the suspension. 60 g. of zinc dust is added in small portions to the acetic mixture.
  • reaction mixture is filtered and the filtrate neutralized with concentrated ammonium hydroxide to precipitate 2-(4-thiazolyl)-benzimidazole.
  • the product is purified by recrystallization from ethyl acetate.
  • 2-(4-thiazolyl)-5-trifluoromethyl benzimidazole is prepared by the method set forth in the preceding paragraph employing 20.5 g. of 3-nitro-4-aminobenzotrifluoride as starting material in place of o-nitroaniline.
  • EXAMPLE 16 3 g. of 2-(4-thiazolyl)-benzimidazole is dissolved in boiling methanol which contains a few drops of phenolphthalein solution. 15 m1. of 1 N sodium methoxide and 2 ml. of dimethyl sulfate are added. After a rapid reaction the solution is no longer alkaline. The same quantities of sodium methoxide and dimethyl sulfate are added again followed by 25 m1. of sodium methoxide solution. The final solution is concentrated to dryness and the residue extracted with benzene. The extracts are treated with activated charcoal and concentrated to a residue of 1- methyl-Z-(4-thiazolyl)-benzimidazole which crystallizes in petroleum ether.
  • R is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl
  • R and R are selected from the class consisting of hydrogen, lower alkyl and trifiuoromethyl groups and acid non-toxic addition salts thereof.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

United rates ?atent Cfilice 3,l7,4l5 Patented Jan. 16, 1962 CERTAEJ BENZHMIHDAZOLES CARRYHNG THHAZ- OLYL, THEADIAZOLYL AND ISQTHIAZGLYL SUBQQTHZUENT EN THE 2 iUSalTiG-N Lewis H. Sarett, Princeton, and Horace D. Brown, Plain field, NJL, assignors to Merck (3a (10., inc, Rahway, NJ, a corporation of New .lersey No Drawing. Filed Jan. 13, 1960, Ser. No. 2,856
12 (Claims. (Cl. 260-602) This invention relates to new compounds useful against helminthiasis. It relates generally to new derivatives of benzimidazole. More particularly, it relates to benzimidazoles having at the 2 position a heterocyclic radical containing nitrogen and sulfur. It is concerned also with methods of making such compounds.
The infection known as helminthiasis involves infestation of the animal body, and particularly the gastrointestinal tract, with various species of parasitic worms. It is a very widespread and serious disease, and the methods heretofore available for its treatment and prevention have not been entirely satisfactory. It is an object of this invention to provide a group of substituted benzimidazoles which are effective in controlling helminthiasis, and which lack many of the objectionable features of the known anthelmintics.
According to the present invention, it has been found that benzimidazoles having at the 2 position of the benzimidazole ring nucleus a heterocyclic radical containing nitrogen and sulfur possess a significant degree of anthelmintic activity and may be effectively employed in the treatment and/or prevention of helm-inthiasis. It is one object of the invention to provide such compounds. It is a more particular object to provide benzimidazoles substituted at the 2 position with a five-membered heterocyclic radical containing nitrogen and sulfur. A further object is provision of methods of synthesizing such compounds. Still other objects will become apparent from the following description of the invention.
The new compounds of our invention have the general structural formula wherein R is a five-membered heterocyclic radical containing nitrogen and sulfur and R is hydrogen, a lower alkyl or a lower alkenyl radical. The invention also includes within its scope acid addition salts of these benzimidazoles.
The five-membered heterocyclic radical (R in the above formula), which is attached to the benzimidazole at one of its carbon atoms, may be a thiazolyl, isothiazolyl or thiadiazolyl radical. When R is a thiazolylor isothiazolyl moiety, the point of attachment to the benzimidazole nucleus may be at any one of the three carbon atoms of the heterocyclic ring, as indicated by the broken lines in the partial structures:
fir t When R is a thiadiazolyl group containing two nitrogen atoms and one sulfur atom in the ring, the radical may be attached to the benzimidazole at either of the two carbon atoms in a 1,2,3-thiadiazle or a 1,2,4-thiadiazole:
N la is) With the symmetrical thiadiazoles, i.e. 1,2,5-thiadiazole or 1,3,4-thiadiazole, only one point of attachment exists u M N N l u The heterocyclic radical may, if desired, be further substituted at a carbon atom with a lower hydrocarbon group such as a lower alkyl radical, the only limitation in this regard being that imposed by the availability of the substituted thiazoles, isothiazoles or thiadiazoles to be used as starting materials. 2-(2-thiazolyl)-benzimidazoles having a lower alkyl group at the 4 position of the thiazole ring and the 2-(5-isothiazolyl)-benzimidazoles having a lower alkyl group at the 3 position of the isothiazole ring such as 2-(4-methyl-2'-thiazolyl) benzimidazole and 2-(3-methyl-5'-isothiazolyl)-benzimidazole are illustrative of this aspect of the invention.
The N-l position of the benzimidazoles (R in Formula I) may be substituted with hydrogen, a lower alkyl group such as methyl, ethyl, propyl or isopropyl, or a lower alkenyl radical of the type represented by allyl and methallyl. The alkyl and alkenyl radicals preferably contain less than six carbon atoms. If desired, the six-membered ring of the benzimidazole nucleus may also be substituted, as with lower alkyl groups at the 5 and/ or 6 positions. Methyl groups are the preferred substituents although ethyl, propyl and similar lower alkyl radicals may, of course, be employed. The so-called pseudo-alkyl radicals, such as a trifluoromethyl substituent, may also be present at the 5 or 6 positions of the benzimidazole.
As representative of the novel substituted benzimidazole compounds falling within the scope of our invention and which may be prepared by the methods discussed hereinbelow, there may be mentioned 2-(2-thiazolyl)-benzimidazole, 2-(4'-thiazolyl)-benzimidazole, 2-(4'-isothiazolyl)- benzimidazole, 2 [4-(1,2,3-thiadiazolyl)] benzimidazole, 2-[5-(1',2,4'-thiadiazolyl)]-benzimidazole, 2-[3- (l',2',5-thiadiazolyl)] benzimidazole, l-methyl-2-[3- (1,2,5-thiadiazolyl)] benzimidazole, l-methyl 2-(2'- thiazolyl) benzimidazole, l-allyl-2-(4'-thiazolyl)-benzimidazole, 2-(5'-thiazolyl)-benzimidazole, 2-[4-(1',2',3'- thiadiazolyl)]-5,6-dimethyl benzimidazole, 2-[4'-(1,2,3'- thiadiazolyl)]-5-methyl benzimidazole, 2-(4-thiazolyl)-5- trifluoromethyl benzimidazole and the like.
The 2-substituted benzimidazoles described herein are isolated as the free bases by the synthetic processes normally employed. They are readily converted to acid addition salts by treatment with acid. Typical salts which may be formed in this manner are mineral acid salts such as the hydrohalides, e.g. hydrochloride, hydrobromide, hydroiodide, sulfates, nitrates, phosphates, and the like, aliphatic acid salts such as the acetate, trimethylacetate, t-butylacetate, or propionate, salts of polycarboxylic acids such as the citrate, oxalate, succinate and the like and salts of other insoluble organic acids such as the embonate and hydroxynaphthoate salts. Certain of these salts are much more water soluble than the free bases. This is true of the hydrohalides. Since the solubility may also be decreased by formation of an appropriate salt, it will be seen that the solubility properties of a particular compound may be generally adjusted by judicious selection of a salt. When the compounds of this invention are used in salt form as anthelmintics, it is, of course, desirable that the particular acid employed be an edible, non-toxic one.
The 2-thiazoly1 benzimidazoles, wherein the point of attachment to the benzimidazole moiety is either the 2 or 4 position of the thiazole ring, represent the preferred compounds of the invention. The preparation of these substances and the other Z-substituted benzimidazoles described herein comprises broadly the reaction of thiazolyl, isothiazolyl or thiadiazolyl carboxylic acid or derivative thereof, such as an ester, amide, nitrile acid halide or aldehyde, with a compound of the general formula R NH:
wherein Y is -NO NH or -NHR, R is lower alkyl or lower alkenyl, and R and R are hydrogen or lower alkyl (or pseudo-alkyl).
According to one process, the Z-heterocyclic benzimidazoles are prepared by reacting together o-phenylenediamine and a heterocyclic carboxylic acid (or derivative thereof) in polyphosphoric acid. The process is carried out at elevated temperatures, and preferably at temperatures of about 150300 C. The optimum reaction time and temperature will of course, depend to some extent on the particular reactants being employed, but in general good yields of the desired compounds are obtained by conducting the process at temperatures of about 175 to about 275 C. for from 2 to 6 hours. When the heterocyclic reactant is one that tends to decompose at elevated temperature, e.g. 4-carboalkoxy-1,2,3-thiadiazole, it is helpful to preheat the reaction mixture at about 100-150 C. for a short period of time, and then to complete the reaction at the higher temperatures referred to above. The heterocyclic carboxylic acid itself may be used as one of the starting compounds or, alternatively, a lower alkyl ester or the amide of such acid may be employed. In cases where the free acid tends to decarboxylate at elevated temperatures, an amide or ester is used as the reactant for best results. For example, thiazole-2-carboxamide is preferred over thiazole-Z-carboxylic acid as starting material in the synthesis of 2-(2-thiazoyl)-benzimidazole since the free acid tends to decompose to thiazole itself at reaction temperature. It is preferred to employ substantially equimolar amounts of the heterocyclic compound and the diamine, and from about 5-20 parts by weight of polyphosphoric acid per part of heterocycle, although it will be appreciated by those skilled in this art that the relative amounts of reactants is not a critical feature of the invention. The desired Z-substituted benzimidazoles are recovered by cooling the reaction mixture and diluting it with water. Where the benzimidazoles do not crystallize readily under these conditions, they are precipitated by neutralizing the quenched mixture with a base such as ammonium hydroxide, an alkali metal hydroxide or an alkali metal carbonate.
Alternatively, the Z-heterocyclic benzimidazole compounds may be synthesized by reacting together o-phenylene-diamine and an aldehydo heterocyclic compound such as thiazole-4-aldehyde or 1,2,3-thiadiazole-4-aldehyde in a reaction medium comprising nitrobenzene. A 1-alkyl-2- heterocyclic benzimidazole, such as 1-methyl-2[4-(1,2, 3'-thiadiazolyl)]-benzimidazole is produced from N- methyl-o-phenylenediamine. Good results are obtained by heating the reaction mixture slowly to the reflux temperature (ca. 210 C.), and maintaining that temperature for a very short time. If desired, a solvent such as a lower alkanol may be used to promote solubility of the reactants at lower temperatures. Such solvents are allowed to distil oil during the heating period. The Z-heterocyclic benzimidazoles are readily recovered. In many cases they crystallize directly on cooling the nitrobenzene solution. Alternatively, they may be crystallized by addition of ether or petroleum ether to the nitrobenzene solution.
According to a further embodiment of the invention,
2-heterocyclic benzimidazoles are prepared by condensation of a heterocyclic aldehyde with a compound of Formula II above. The reaction is preferably brought about in a suitable solvent such as a lower alkanol, e.g. methanol, ethanol, isopropanol or t-butanol. The first product formed is the Schiff base of the aldehyde and the primary amine. In normal practice this is not isolated but rather converted directly to the benzimidazole. When an o-phenylenediame or an N-substituted-o-phenylenediame is used, the ring closure of the Schiff base to the 2-heterocyclic benzimidazole is effected with a suitable oxidizing agent such as cupric acetate, lead tetracetate, mercuric acetate, air and the like.
Alternatively, in those cases where an o-nitroaniline is one of the starting materials, an ester or an acid halide derivative of the hetrocycle is employed. An intermediate anilide is formed initially. The nitro group is then reduced and benzimidazole formation effected by treatment of the intermediate anilide with a reducing system such as zinc-hydrochloric acid or zinc-acetic acid.
Where a heavy metal reagent is used to bring about benzimidazole formation from an o-phenylenediamine in the above two processes, an insoluble heavy metal salt of the Z-heterocyclic benzimidazole is formed. This material is readily converted to the free benzimidazole by removal of the heavy metal with reagents suitable for this purpose such as hydrogen sulfide, ammonium polysulfide, ammonium hydroxide and the like.
In an additional embodiment of our invention 2-heterocyclic benzimidazoles are prepared by heating a mixture of an o-phenylenediame or an N-alkyl-o-phenylenedi amine and a lower alkyl heterocyclic carboxylate with an aqueous mineral acid such as aqueous sulfuric or phosphoric acid in a closed system, i.e. an autoclave or bomb. The process is conducted at temperatures of from about 180 C. for 3-10 hours, and the 2-hetero cyclic benzimidazole recovered from the acid reaction mixture by application of the isolation and purification techniques described hereinabove.
1-substituted-Z-heterocyclic benzimidazoles, where R in Formula. I above is alkyl or alkenyl, may further be synthesized by alkylation or alkenylation of the 2-hetero' cyclic benzimidazole itself. According to this method, an alkali metal salt of the benzimidazole is reacted with an ester of a strong acid and a lower alkanol or lower alkenol, such as methyl bromide, methyl iodide, allyl bromide and the like, or with an alkyl sulfate such as dimethyl sulfate.
The Z-Substituted benzimidazoles described herein have a high degree of anthelmintic activity and are useful in the treatment and/ or prevention of helminthiasis, a parasitic disease which causes widespread and often serious infection in domesticated animals such as swine, ruminants such as cattle and sheep and even in man. In treating domesticated animals, the compounds are mixed with a non-toxic edible carrier to form a feed supplement which is then incorporated in the animal feed in the desired concentration, or they may be administered in unit dosage forms which, in the case of large domesticated animals, take the form of boluses, or in the form of a liquid drench. Alternatively, water soluble salts or a dispersable, wettable powder containing the 2-heterocyclic benzimidazole may be added to the drinking water of the animals.
The following examples are given for the purposes of illustration and not by way of limitation:
cooled and poured into excess ice water with stirring. The resulting red solution is filtered to remove a small amount of black insoluble material and then treated with decolorizing charcoal. The charcoal is removed by filtration, and the filtrate treated with 50% sodium hydroxide solution until just pink to phenolphthalein paper. The resulting precipitate is filtered ofi? and Washed with water. It is then dissolved in a minimum amount of boiling ethanol, treated with decolorizing charcoal, and the charcoal removed by filtration. Water is added to the boiling filtrate until its total volume is about 250 ml. 2-(2'-thiazolyl)-benzimidazole crystallizes out immediately. The product is filtered, washed with cold 30% ethanol, and air dried, M.P. 245-246 C. A second crop of product, M.P. 245 C., is obtained by concentrating the filtrate to a small volume and cooling.
EXAMPLE 2 2-(4-thiazolyl) -benzimidazle Three g. of thiazole-4-carboxylic acid hydro-bromide (14.3 m. mole) and 2 g. of o-phenylenediamine (18.5 m. mole) are mixed and added to 60 g. of polyphosphoric acid. The mixture is heated slowly with stirring to 240 C. and maintained at this temperature for 3 hours. The hot solution is then poured onto about 200 g. of ice. A tafiy-like mass separates which dissolves on stirring. The mixture is filtered and the filtrate neutralized with 30% sodium hydroxide. At a pH of about 6, 2-(4'- thiazolyl) benzimidazole precipitates. It is filtered, washed with water, and dried in air, M.P. 296298 C.
This product is extracted with boiling ethanol. Some benzene is added to the extract and the solution boiled to remove traces of water. On concentration of the solution to a small volume and cooling. 2-(4-thiazolyl)- benzimidazole crystallizes, M.P. 301-302 C.
EXAMPLE 3 2- [4 (1 ,2 ,3 '-thiadiaz0lyl l-benzimidazole 6.0 g. of 4-carbethoxy-1,2,3-thiadiazole and 8.0 g. of o-phenylenediamine are added to 120 g. of polyphosphoric acid preheated to about 80 C. in a nitrogen atmosphere. After stirring for one hour at 125 C. the temperature is raised to 225 C. for one hour. The brown solution is cooled to about 100 C. and poured (with stirring) in a thin stream into 200 cc. of cold water. A dark green amorphous solid is filtered OE and the filtrate neutralized to pH ca. 7 With sodium hydroxide solution. The crystalline solid which precipitates is filtered, washed with water and dried. Extraction of this solid with several 200 ml. portions of acetone, treatment of the solution with Darco, filtration and removal of the solvent gives almost colorless crystals of 2[4-(1',2,3'-thiadiazolyl)]-benzimidazole, M.P. 255-8 C.
EXAMPLE 4 2- [3 1 ,2',5 -thiadiazolyl) -benzimidaz0le 12.8 g. (0.081 mole) of 3-carbethoxy-1,2,5-thiadiazole, 11 g. (0.1 mole) of o-phenylenediamine and 50 g. of polyphosphoric acid are mixed and heated with stirring at 175 C. in a nitrogen atmosphere for 3 hours. At this time, the dark solution is cooled to about 100 C. and then slowly poured with stirring into about 500 ml. of cold water. The tacky threads slowly change to a brown solid. The suspension is neutralized to pH ca. 7 to precipitate the remainder of the product. The solid is washed with water, sodium bicarbonate solution to insure neutrality and dried in air. The 2-[3'-(1,2,5'- thiadiazolyl)J-benzimidazole is then recrystallized from ethyl acetate solution with a decolorizing charcoal treatment, M.P. 26870 C. (sublimation 240). Recrystalization from ethyl acetate raises the M.P. to 272 274 C.
EXAMPLE 2-(4'thiaz0lyl)-5-methyl benzimidazole 30.4 g. of 4-methyl-2-nitroaniline in 400 ml. of ethanol is treated with hydrogen at a pressure of about lbs; per square inch in the presence of 4 g. of 5% paladium on charcoal catalyst. A pressure drop of 23 lbs. per square inch takes place. The solut on is filtered and 22.6 g. of 4-thiazole aldehyde is added to the colored filtrate containing the methylated o-phenylenediarnine. The reaction mixture is stirred at room temperature for one hour during which time the Schifi base forms.
40 g. of cupric acetate monohydrote in 400 ml. of water is added to the above solution in small portions. The reaction mixture is heated under slight reflux with stirring to complete the precipitation of the copper salt of 2-(4'- thiazolyl)-S-rnethyl benzimidazole. The mixture is then cooled, filtered and the green solid washed with water. The solid salt is then suspended in about 500 ml. of ethanol and the mixture saturated with a slow stream of hydrogen sulfide. The precipitated copper sulfide is removed by filtration and the filtrate concentrated in vacuo to obtain crystalline 2-(4'-thiazolyl)-5-methyl benzimidazole.
The hydrobromide salt of this product is prepared by dissolving the product in hot alcoholic hydrogen bromide, treating the hot solution with activated charcoal, removing the charcoal by filtration, and adding about 3 volumes of ether to the alcoholic solution. The hydrobromide salt crystallizes on cooling.
EXAMPLE 6 l-methyl-Z-(4-thiaz0lyl)-benzimidaz0le A. To 10 g. of 2-(4-thiazolyl)-benzirnidazole in 100 m1. of dry dimethylformamide is added 2.3 g. of a 52% sodium hydride emulsion in mineral oil. The mixture is stirred at room temperature for about 20 minutes and then warmed carefully to about C. for 10 minutes. It is cooled to room temperature and 7.1 g. of methyl iodide in 10 ml. of dimethylformamide is added slowly to the cooled solution. The reaction mixture is then heated to about 80 C. for 20 minutes, cooled, diluted with 200 ml. of water and extracted with three l00-ml. portions of ether. The ether extracts are combined, washed with water, dried over sodium sulfate, filtered and the ether removed in vacuo to give l-rnethyl-Z- (4-thiazolyl)-benzirnidazole which may be purified by crystallization from ethyl acetate.
When the above process is carried out employing allyl bromide in place of methyl bromide, l-allyl-2(4--thiazolyl)-benzimidazole is obtained.
B. The above product is also produced by adding 5 g. of N-methyl-o-phenylenediamine dihydrochloride in 75 ml. of 50% alcohol to a solution of 10 g. of cupric acetate and 6 g. of thiazole-4-aldehyde in 300 ml. of Water. The addition is carried out at about 0 C. and the reaction mixture is then heated in a hot water bath for about 30 minutes.
The resulting brown solid is recovered by filtration and washed with cold water and ethanol. It is then suspended in dilute hydrochloric acid and a stream of hydrogen sulfide bubbled slowly through the suspension until it is saturated with hydrogen sulfide. It is filtered and the filtrate obtained after removal of the copper sulfide is concentrated to dryness and the residue dissolved in a small volume of water. The solution is neutralized with potassium carbonate solution and extracted with chloroform. The chloroform extract is concentrated to dryness and the resulting residue extracted with petroleum ether. On concentration of the petroleum ether extracts, to a small volume, 1-methyl-2-(4-thiazolyl) -benzimidazole precipitates.
EXAMPLE 7 2-(4'-methyl-2'-thiaz0lyl)-benzimidaz0le 17 g. of 2-carbethoxy-4-methyl thiazole is added with stirring to 11 g. of o-phenylenediamine in g. of polyphosphoric acid. The resulting viscous mixture is heated slowly with stirring to about 125 C. and stirred at this temperature for 1 hour. The volatile material is allowed to escape through an air-cooled condenser. The temperature is then raised to 175 C. for 3 hours. At the end of this time, the reaction mixture is cooled and poured into excess ice water. The 2-(4'-methyl-2-thiazolyl)-benzimidazole is recovered according to the isolation procedure described in Example 1.
The hydrochloride salt is obtained by treatment of the base with ethanolic hydrogen chloride by the method described in Example 10.
EXAMPLE 8 2-(2'-thiaz0lyl) -benzimidazole To 11 g. of o-phenylenediamine in 100 ml. of ethanol is added with stirring 11.3 g. of thiazole-Z-aldehyde in 100 ml. of ethanol. This mixture is stirred for about 1 hour at room temperature after which time 20 g. of cupric acetate monohydrate in 200 ml. of water is added dropwise with rapid stirring. After this addition is completed, the reaction mixture is heated at gentle reflux for about 30 minutes. It is then cooled and the copper salt recovered by filtration and washed with water. It is then suspended in 250 ml. of 95% ethanol and saturated with hydrogen sulfide (with stirring). The insoluble copper sulfide is removed by filtering and the clear filtrate concentrated essentially to dryness. The 2-(2'-thiazolyl)- benzimidazole thus obtained is purified by recrystallization from aqueous ethanol.
EXAMPLE 9 2- (4 -thiazlyl -benzimidaz0le 22.6 g. of thiazole-4-aldehyde in 25 ml. of methanol is added to a suspension of 22 g. of o-phenylenediamine in 75 ml. of nitrobenzene. The resulting mixture is stirred at room temperature for a few minutes and then heated slowly to 210 C. for one minute. During the heating period, the methanol is removed by distillation. The reaction mixture is then cooled with stirring to about 10 C. whereupon the 2-(4'-thiazolyl)-benzimidazole crystallizes. It is filtered off and washed with ether. Any nitrobenzene remaining with the product is removed by recrystallization of the benzimidazole from alcohol.
EXAMPLE 10 A. 5 g. of 2-(2-thiazolyl)-benzimidazole is added with stirring to 100 ml. of ethanol saturated with dry hydrogen chloride. An additional 125 ml. of ethanol is added to give a dark brown solution. The solution is treated with 5 g. of activated charcoal and the charcoal removed by filtration. The clear filtrate is diluted with three times its volume of ethyl ether and the resulting mixture chilled. After a short time, crystals of 2-(2'-thiazolyl)-benzimidazole monohydrochloride appear, M.P. 246 C.
B. 5 g. of 2-(4'-thiazolyl)-benzimidazole is added at room temperature to 100 ml. of absolute ethanol saturated with dry hydrogen chloride. An additional 150 ml. of ethanol is added and the mixture warmed to give a clear solution. This warm solution is treated with 3 g. of activated charcoal and the charcoal removed by filtration. The resulting solution is diluted with dry ethyl ether to a volume of one liter. On cooling and chilling in an ice bath, 2-(4--thiazolyl)-benzimidazole monohydrochloride crystallizes. The product sublimes at about 265 C.
C. 50 mg. of 2-(4-thiazolyl)-benzimidazole in 5 ml. of ethanol is treated with 3 drops of 50% sulfuric acid. Dilution of the mixture With ether to turbidity and cooling yields the colorless sulfate salt of 2-(4'-thiazolyl)- benzimidazole, M.P. 262-266 C.
EXAMPLE 1 1 2-(5'-thiazolyl) -benzimidaz0le 13.2 g. of thiazole-S-carboxamide, 11.5 g. of o-phenylenediamine and 272 g. of polyphosphoric acid are reacted according to the procedure of Example 1 above. The crude product obtained is recrystallized from ethyl acetate to give substantially pure 2-(5'-thiaz0lyl)-benzi midazole, M.P. 294-295 C.
EXAMPLE 12 2(4-tlziaz0lyl)-5,6-dimethyl benzimidazole 8 g. of 4-thiazolyl aldehyde in ml. of ethanol is added at room temperature to 10 g. of 4,5-dimethyl-ophenylenediamine in 200 ml. of ethanol. The mixture is stirred for one hour at room'temperature and a solution of 16 g. of cupric acetate in 400 ml. of water is added in small portions. When formation of the insoluble copper salt of 2-(4-thiazoly1)-5,6-dimethy1 benzimidazole is complete, the product is recovered by filtration, washed with water and treated with hydrogen sulfide as described in Example 5. After removal of the insoluble copper sulfide, the filtrate is treated with decolorizing charcoal, filtered, and the solvent removed in vacuo to give 2-(4'- thiazolyl)-5,6-dimethyl benzimidazole which is purified by recrystallization from ethyl acetate.
EXAMPLE 13 2-(4'-is0thiaz0lyl)-benzimidaz0le 15 g. of 4-carbethoxy isothiazole is added at room temperature to 11 g. of o-phenylenediamine in 150 g. of polyphosphoric acid. The mixture is stirred and the temperature raised to C. for 2 hours. It is then heated at 175 C. for an additional 2 hours. The mixture is then poured into 1 liter of ice water and neutralized to a pH of about 6 with sodium hydroxide whereupon 2-(4-isothiazoly1)-benzimidazole precipitates. The product is filtered off and extracted with hot acetone. The acetone extracts are treated with decolorizing charcoal and the filtrate obtained after removal of the charcoal is concentrated to dryness in vacuo to give the desired product.
EXAMPLE 14 2-(3'-methyl-5'-is0thiaz0lyl) -benzimidaz0le 32 g. of S-methyl-S-carbomethoxy isothiazole are reacted with 22 g. of o-phenylenediarnine in 175 g. of polyphosphoric acid according to the procedure set forth in Example 13. There is obtained in this fashion 2-(3? methyl-5 '-isothiazolyl -benzimidazole.
EXAMPLE 15 2-(4-thiaz0lyl) -benzimidaz0le 13 g. of 4-thiazolyl acid chloride and 13 g. of o-nitroaniline are stirred together in 35 ml. of pyridine at room temperature for about 12 hours. At the end of this time, the mixture is quenched in ice water and the solid nitroanilide recovered by filtration and Washed with dilute sodium carbonate solution. The solid is suspended in ml. of glacial acetic acid, and 80 ml. of o-N-hydrochloric acid added to the suspension. 60 g. of zinc dust is added in small portions to the acetic mixture. After the zinc addition is complete, and the reaction is essentially finished (by visual observation), the reaction mixture is filtered and the filtrate neutralized with concentrated ammonium hydroxide to precipitate 2-(4-thiazolyl)-benzimidazole. The product is purified by recrystallization from ethyl acetate. The acid chloride employed as starting material is obtained by treating 4-carboxy thiazole =with thionyl chloride by known methods.
2-(4-thiazolyl)-5-trifluoromethyl benzimidazole is prepared by the method set forth in the preceding paragraph employing 20.5 g. of 3-nitro-4-aminobenzotrifluoride as starting material in place of o-nitroaniline.
EXAMPLE 16 3 g. of 2-(4-thiazolyl)-benzimidazole is dissolved in boiling methanol which contains a few drops of phenolphthalein solution. 15 m1. of 1 N sodium methoxide and 2 ml. of dimethyl sulfate are added. After a rapid reaction the solution is no longer alkaline. The same quantities of sodium methoxide and dimethyl sulfate are added again followed by 25 m1. of sodium methoxide solution. The final solution is concentrated to dryness and the residue extracted with benzene. The extracts are treated with activated charcoal and concentrated to a residue of 1- methyl-Z-(4-thiazolyl)-benzimidazole which crystallizes in petroleum ether.
Any departure from the above description which conforms to the present invention is intended to be included Within the scope of the claims.
What is claimed is:
1. 2-(2'-thiazolyl)-benzimidazole.
2. 2-(4'-thiazolyl)-benzimidazole.
5. 2-(4'-thiazolyl)-benzimidazole hydrochloride.
6. 2(4'-thiazoly1)-5,6-dimethyl benzimidazole.
7. 2-(2-thiazolyl)-benzimidazole hydrochloride.
8. A 'benzimidazole having the formula lls.
from the class consisting of thiazolyl, thiadiazolyl and isothiazolyl rings wherein one carbon atom of said ring is attached to the benzimidazole ring and the remaining carbon atoms of said ring are substituted with a member of the class consisting of hydrogen and lower alkyl groups, R is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, and R and R are selected from the class consisting of hydrogen, lower alkyl and trifiuoromethyl groups and acid non-toxic addition salts thereof.
9. Z-thiazolyl benzimidazole.
10. Z-thiadiazolyl benzimidazole.
l1. 2-isot hiazolyl benzimidazole.
12. A non-toxic acid addition salt of Z-thiazolyl benzimidazole.
Elderfield: Heterooyclic Compounds, v01. 5, pp. 281- 284 (1957).
Elderfield: Heterocyclic Compounds, vol. 5, pp. 205, 274-9 (1957).
UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3,017,415 January 16, 1962 Lewis H. Sarett et a1.
It is hereby certified that error appears in the above numbered patent requiring correction and that the said Letters Patent should read as corrected below.
Column 3, line 7, after "nitrile" insert a comma;
column 10, line 9, for "acid non-toxic" read non-toxic acid Signed and sealed this 10th day of Augtist 1965.
(SEAL) Auest:
ERNEST W, SWIDER' EDWARD J. BRENNER Attesting Officer Commissioner of Patents

Claims (1)

1. 2-(2''-THIAZOLYL)-BENZIMIDAZOLE.
US2856A 1960-01-18 1960-01-18 Certain benzimidazoles carrying thiazolyl, thiadiazolyl and isothiazolyl substituents in the 2 position Expired - Lifetime US3017415A (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
BE599143D BE599143A (en) 1960-01-18
US2856A US3017415A (en) 1960-01-18 1960-01-18 Certain benzimidazoles carrying thiazolyl, thiadiazolyl and isothiazolyl substituents in the 2 position
US15518A US3055907A (en) 1960-01-18 1960-03-17 Acyl benzimidazoles and method of preparing same
DEM45481A DE1235321B (en) 1960-01-18 1960-06-01 Process for the preparation of substituted benzimidazoles and their salts
GB20378/60A GB948635A (en) 1960-01-18 1960-06-09 Benzimidazole
ES0263822A ES263822A1 (en) 1960-01-18 1961-01-04 Certain benzimidazoles carrying thiazolyl, thiadiazolyl and isothiazolyl substituents in the 2 position
FR849060A FR1423609A (en) 1960-01-18 1961-01-06 Benzimidazole derivatives and their manufacturing process
CH1531665A CH423791A (en) 1960-01-18 1961-01-17 Process for the production of a benzimidazole
CH1531565A CH423790A (en) 1960-01-18 1961-01-17 Process for the production of a benzimidazole
CH1531865A CH423793A (en) 1960-01-18 1961-01-17 Process for the preparation of 1-alkyl and 1-alkenylbenzimidazoles
SE436/61A SE310883B (en) 1960-01-18 1961-01-17
CH1531765A CH423792A (en) 1960-01-18 1961-01-17 Process for the preparation of 1-acyl-2-substituted benzimidazoles
CH49061A CH423789A (en) 1960-01-18 1961-01-17 Process for the production of a benzimidazole
DK19761AA DK107167C (en) 1960-01-18 1961-01-17 Process for the preparation of benzimidazole compounds or acid addition salts thereof.
OA51102A OA00999A (en) 1960-01-18 1964-12-29 Benzimidazole derivatives and their manufacturing process.
CY30965A CY309A (en) 1960-01-18 1965-02-18 Benzinide
MY196575A MY6500075A (en) 1960-01-18 1965-12-31 Benzimidazoles
SE11797/67A SE320977B (en) 1960-01-18 1967-08-23

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2856A US3017415A (en) 1960-01-18 1960-01-18 Certain benzimidazoles carrying thiazolyl, thiadiazolyl and isothiazolyl substituents in the 2 position
US15518A US3055907A (en) 1960-01-18 1960-03-17 Acyl benzimidazoles and method of preparing same

Publications (1)

Publication Number Publication Date
US3017415A true US3017415A (en) 1962-01-16

Family

ID=26670973

Family Applications (2)

Application Number Title Priority Date Filing Date
US2856A Expired - Lifetime US3017415A (en) 1960-01-18 1960-01-18 Certain benzimidazoles carrying thiazolyl, thiadiazolyl and isothiazolyl substituents in the 2 position
US15518A Expired - Lifetime US3055907A (en) 1960-01-18 1960-03-17 Acyl benzimidazoles and method of preparing same

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15518A Expired - Lifetime US3055907A (en) 1960-01-18 1960-03-17 Acyl benzimidazoles and method of preparing same

Country Status (12)

Country Link
US (2) US3017415A (en)
BE (1) BE599143A (en)
CH (5) CH423790A (en)
CY (1) CY309A (en)
DE (1) DE1235321B (en)
DK (1) DK107167C (en)
ES (1) ES263822A1 (en)
FR (1) FR1423609A (en)
GB (1) GB948635A (en)
MY (1) MY6500075A (en)
OA (1) OA00999A (en)
SE (2) SE310883B (en)

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3183239A (en) * 1961-02-23 1965-05-11 Merck & Co Inc 5-ether and 5-thioether-2-heterocyclic benzimidazoles
US3239532A (en) * 1960-04-07 1966-03-08 Geigy Ag J R Certain diazolylmethyl esters of thiophosphoric and dithiophosphoric acids
US3299080A (en) * 1962-07-05 1967-01-17 Merck & Co Inc Processes and intermediates for preparing certain 2-thiazolylbenzimidazoles
DE1237731B (en) * 1963-05-23 1967-03-30 Merck & Co Inc Means to combat fungus growth
US3324102A (en) * 1963-01-31 1967-06-06 Merck & Co Inc Water-soluble benzimidazole-containing coordination compounds and methods relating thereto
US3347908A (en) * 1963-06-24 1967-10-17 Merck & Co Inc Nu-lactoyl and nu-halopyruvoyl-2-nitroanilides
US3350211A (en) * 1964-12-31 1967-10-31 Merck & Co Inc Compositions useful in controlling marine fouling and methods for their use
US3361756A (en) * 1963-11-29 1968-01-02 Merck & Co Inc 2-(alpha-haloalkanoyl) benzimidazoles
US3398157A (en) * 1964-12-31 1968-08-20 Merck & Co Inc Process for preparing benzimidazole nu-oxides
US3429890A (en) * 1964-12-31 1969-02-25 Merck & Co Inc Certain 2-thiazolylbenzimidazole-1-oxy derivatives
US3471508A (en) * 1963-11-06 1969-10-07 Merck & Co Inc 5-aryl (or heteroaromatic) benzazoles
US3475444A (en) * 1966-02-18 1969-10-28 Merck & Co Inc Complexes of 2-substituted benzimidazoles and bis-halogenated phenols
US3478046A (en) * 1963-11-19 1969-11-11 Merck & Co Inc 5-(or 6)-halo(or amino)benzazoles and methods for preparing same
US3484519A (en) * 1965-12-02 1969-12-16 Merck & Co Inc Anthelmintic 2-substituted benzimidazole-metal arsenate compositions and method
US3506678A (en) * 1967-02-21 1970-04-14 Merck & Co Inc Certain 2-substituted thieno(2,3-d) imidazoles
US3535331A (en) * 1967-07-26 1970-10-20 Merck & Co Inc Water-soluble 2-substituted benzimidazole hypophosphite salts
US3538108A (en) * 1967-08-17 1970-11-03 Merck & Co Inc Water - soluble 2 - substituted benzimidazole methanesulfonic acid salts
US3546341A (en) * 1966-02-18 1970-12-08 Merck & Co Inc Complexes of 2-substituted benzimidazoles and bis-halogenated phenols in anthelmintic compositions and methods
US3711608A (en) * 1971-04-13 1973-01-16 Merck & Co Inc The treatment of pain, fever and inflammation with benzimidazoles
US3899503A (en) * 1974-01-25 1975-08-12 Morton Norwich Products Inc Process for preparing 2-(2{40 )-furyl-, 2-(2{40 )-thienyl- 2-(4{40 )-thiazolyl- or 2-(2{40 )-pyrryl-5 (or 6) nitrobenzimidazole
US3928372A (en) * 1967-12-06 1975-12-23 Merck & Co Inc 2-(3-Oxythiazolyl)benzimidazoles
US3998785A (en) * 1974-06-13 1976-12-21 International Business Machines Corporation Anti-fungal and/or anti-bacterial hardware for ink printing apparatus
US4006259A (en) * 1975-04-01 1977-02-01 Fmc Corporation Preservative coating for fruits and vegetables
US4247442A (en) * 1978-03-29 1981-01-27 Toray Silicone Company, Ltd. Mold and mildew resistant organopolysiloxane compositions
JPS6351305A (en) * 1985-06-05 1988-03-04 ユニロイヤル リミテツド Synergistic fungicidal composition
AU596635B2 (en) * 1986-01-27 1990-05-10 Shell Internationale Research Maatschappij B.V. Fungicidal compositions
US5013746A (en) * 1988-04-08 1991-05-07 Janssen Pharmaceutica N.V. Imazalil containing synergistic compositions
WO2004047769A3 (en) * 2002-11-26 2004-09-10 Isis Pharmaceuticals Inc Benzimidazoles and analogs thereof as antibacterials
US20050148639A1 (en) * 2002-03-21 2005-07-07 Basf Aktiengesellschaft Fungicidal mixtures
WO2009040397A1 (en) 2007-09-26 2009-04-02 Basf Se Ternary fungicidal compositions comprising boscalid and chlorothalonil
US20090191138A1 (en) * 2008-01-30 2009-07-30 Mediquest Therapeutics, Inc. Novel topical formulations for improving the appearance of nails
US20100130513A1 (en) * 2002-12-03 2010-05-27 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
EP2258177A2 (en) 2006-12-15 2010-12-08 Rohm and Haas Company Mixtures comprising 1-methylcyclopropene
WO2011026796A1 (en) 2009-09-01 2011-03-10 Basf Se Synergistic fungicidal mixtures comprising lactylates and method for combating phytopathogenic fungi
EP2392662A2 (en) 2007-04-23 2011-12-07 Basf Se Plant produtivity enhancement by combining chemical agents with transgenic modifications
CN102388909A (en) * 2011-10-13 2012-03-28 光华化学股份有限公司 Complex pesticide composition containing oxine-copper and thiabendazole
WO2012084670A1 (en) 2010-12-20 2012-06-28 Basf Se Pesticidal active mixtures comprising pyrazole compounds
EP2481284A2 (en) 2011-01-27 2012-08-01 Basf Se Pesticidal mixtures
EP2489267A2 (en) 2006-09-18 2012-08-22 Basf Se Pesticidal mixtures comprising an anthranilamide insecticide and a fungicide
WO2012127009A1 (en) 2011-03-23 2012-09-27 Basf Se Compositions containing polymeric, ionic compounds comprising imidazolium groups
WO2013030338A2 (en) 2011-09-02 2013-03-07 Basf Se Agricultural mixtures comprising arylquinazolinone compounds
WO2013189801A1 (en) 2012-06-20 2013-12-27 Basf Se Pyrazole compound and pesticidal mixtures comprising a pyrazole compound
EP2679096A1 (en) 2007-02-06 2014-01-01 Basf Se Pesticidal mixtures
WO2014056780A1 (en) 2012-10-12 2014-04-17 Basf Se A method for combating phytopathogenic harmful microbes on cultivated plants or plant propagation material
WO2014095994A1 (en) 2012-12-20 2014-06-26 Basf Se Compositions comprising a triazole compound
EP2783569A1 (en) 2013-03-28 2014-10-01 Basf Se Compositions comprising a triazole compound
EP2835052A1 (en) 2013-08-07 2015-02-11 Basf Se Fungicidal mixtures comprising pyrimidine fungicides
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
WO2015036058A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
EP2979549A1 (en) 2014-07-31 2016-02-03 Basf Se Method for improving the health of a plant
WO2017001252A1 (en) 2015-07-02 2017-01-05 BASF Agro B.V. Pesticidal compositions comprising a triazole compound
US10899932B2 (en) 2014-10-24 2021-01-26 Basf Se Non-amphoteric, quaternisable and water-soluble polymers for modifying the surface charge of solid particles

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625954A (en) * 1968-03-20 1971-12-07 Pfizer 1-aroylbenzimidazoles
US3864351A (en) * 1971-10-04 1975-02-04 Pfizer 1-({60 -Carboxymethoxybenzoyl-2-(2{40 -pyridyl)benzimidazoles
US4017504A (en) * 1975-06-12 1977-04-12 Merck & Co., Inc. Antifungal 1-substituted benzimidazoles
US4017503A (en) * 1975-06-12 1977-04-12 Merck & Co., Inc. Antifungal 1-substituted benzimidazoles
WO1990010630A1 (en) * 1989-03-15 1990-09-20 Janssen Pharmaceutica N.V. [5(6)-(benzisoxa-, benzisothia- or indazol-3-yl)-1h-benzimidazol-2-yl] carbamates
NZ232785A (en) * 1989-03-15 1991-03-26 Janssen Pharmaceutica Nv 5-(1,2 benzisoxazol-, benzimidazol and benzisothiazol-3- yl)-1h-benzimadazol-2-yl carbamic acid ester derivatives preparatory processes, intermediates and anthelmintic compositions
US5310924A (en) * 1993-04-30 1994-05-10 E. I. Du Pont De Nemours And Company Process for preparing thiabendazole

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2985661A (en) * 1956-02-06 1961-05-23 American Cyanamid Co Preparation of 2(omicron-aminophenyl)-benzimidazole

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483392A (en) * 1949-10-04 Substituted ethylenes and process

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2985661A (en) * 1956-02-06 1961-05-23 American Cyanamid Co Preparation of 2(omicron-aminophenyl)-benzimidazole

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239532A (en) * 1960-04-07 1966-03-08 Geigy Ag J R Certain diazolylmethyl esters of thiophosphoric and dithiophosphoric acids
US3183239A (en) * 1961-02-23 1965-05-11 Merck & Co Inc 5-ether and 5-thioether-2-heterocyclic benzimidazoles
US3299080A (en) * 1962-07-05 1967-01-17 Merck & Co Inc Processes and intermediates for preparing certain 2-thiazolylbenzimidazoles
US3324102A (en) * 1963-01-31 1967-06-06 Merck & Co Inc Water-soluble benzimidazole-containing coordination compounds and methods relating thereto
DE1237731B (en) * 1963-05-23 1967-03-30 Merck & Co Inc Means to combat fungus growth
US3370957A (en) * 1963-05-23 1968-02-27 Merck & Co Inc Antifungal compositions and methods for their use
US3347908A (en) * 1963-06-24 1967-10-17 Merck & Co Inc Nu-lactoyl and nu-halopyruvoyl-2-nitroanilides
US3471508A (en) * 1963-11-06 1969-10-07 Merck & Co Inc 5-aryl (or heteroaromatic) benzazoles
US3478046A (en) * 1963-11-19 1969-11-11 Merck & Co Inc 5-(or 6)-halo(or amino)benzazoles and methods for preparing same
US3361756A (en) * 1963-11-29 1968-01-02 Merck & Co Inc 2-(alpha-haloalkanoyl) benzimidazoles
US3350211A (en) * 1964-12-31 1967-10-31 Merck & Co Inc Compositions useful in controlling marine fouling and methods for their use
US3429890A (en) * 1964-12-31 1969-02-25 Merck & Co Inc Certain 2-thiazolylbenzimidazole-1-oxy derivatives
US3398157A (en) * 1964-12-31 1968-08-20 Merck & Co Inc Process for preparing benzimidazole nu-oxides
US3484519A (en) * 1965-12-02 1969-12-16 Merck & Co Inc Anthelmintic 2-substituted benzimidazole-metal arsenate compositions and method
US3546341A (en) * 1966-02-18 1970-12-08 Merck & Co Inc Complexes of 2-substituted benzimidazoles and bis-halogenated phenols in anthelmintic compositions and methods
US3475444A (en) * 1966-02-18 1969-10-28 Merck & Co Inc Complexes of 2-substituted benzimidazoles and bis-halogenated phenols
US3506678A (en) * 1967-02-21 1970-04-14 Merck & Co Inc Certain 2-substituted thieno(2,3-d) imidazoles
US3535331A (en) * 1967-07-26 1970-10-20 Merck & Co Inc Water-soluble 2-substituted benzimidazole hypophosphite salts
US3538108A (en) * 1967-08-17 1970-11-03 Merck & Co Inc Water - soluble 2 - substituted benzimidazole methanesulfonic acid salts
US3928372A (en) * 1967-12-06 1975-12-23 Merck & Co Inc 2-(3-Oxythiazolyl)benzimidazoles
US3711608A (en) * 1971-04-13 1973-01-16 Merck & Co Inc The treatment of pain, fever and inflammation with benzimidazoles
US3899503A (en) * 1974-01-25 1975-08-12 Morton Norwich Products Inc Process for preparing 2-(2{40 )-furyl-, 2-(2{40 )-thienyl- 2-(4{40 )-thiazolyl- or 2-(2{40 )-pyrryl-5 (or 6) nitrobenzimidazole
US3998785A (en) * 1974-06-13 1976-12-21 International Business Machines Corporation Anti-fungal and/or anti-bacterial hardware for ink printing apparatus
US4006259A (en) * 1975-04-01 1977-02-01 Fmc Corporation Preservative coating for fruits and vegetables
US4247442A (en) * 1978-03-29 1981-01-27 Toray Silicone Company, Ltd. Mold and mildew resistant organopolysiloxane compositions
JPS6351305A (en) * 1985-06-05 1988-03-04 ユニロイヤル リミテツド Synergistic fungicidal composition
AU596635B2 (en) * 1986-01-27 1990-05-10 Shell Internationale Research Maatschappij B.V. Fungicidal compositions
US5013746A (en) * 1988-04-08 1991-05-07 Janssen Pharmaceutica N.V. Imazalil containing synergistic compositions
US20100160399A1 (en) * 2002-03-21 2010-06-24 Basf Aktiengessellschaft Fungicidal mixtures
US8188001B2 (en) 2002-03-21 2012-05-29 Basf Aktiengesellschaft Fungicidal mixtures
EP2080433A2 (en) 2002-03-21 2009-07-22 Basf Se Fungicidal mixtures
US20050148639A1 (en) * 2002-03-21 2005-07-07 Basf Aktiengesellschaft Fungicidal mixtures
US7683086B2 (en) 2002-03-21 2010-03-23 Basf Aktiengesellschaft Fungicidal mixtures
WO2004047769A3 (en) * 2002-11-26 2004-09-10 Isis Pharmaceuticals Inc Benzimidazoles and analogs thereof as antibacterials
US20100130513A1 (en) * 2002-12-03 2010-05-27 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US8207173B2 (en) 2002-12-03 2012-06-26 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
EP2489266A2 (en) 2006-09-18 2012-08-22 Basf Se Pesticidal mixtures comprising an anthranilamide insecticide and a fungicide
EP2489265A2 (en) 2006-09-18 2012-08-22 Basf Se Pesticidal mixtures comprising an anthranilamide insecticide and a fungicide
EP2489267A2 (en) 2006-09-18 2012-08-22 Basf Se Pesticidal mixtures comprising an anthranilamide insecticide and a fungicide
EP2489268A2 (en) 2006-09-18 2012-08-22 Basf Se Pesticidal mixtures comprising an anthranilamide insecticide and a fungicide
EP2258177A2 (en) 2006-12-15 2010-12-08 Rohm and Haas Company Mixtures comprising 1-methylcyclopropene
EP2679094A1 (en) 2007-02-06 2014-01-01 Basf Se Pesticidal mixtures
EP2679095A1 (en) 2007-02-06 2014-01-01 Basf Se Pesticidal mixtures
EP2679096A1 (en) 2007-02-06 2014-01-01 Basf Se Pesticidal mixtures
EP2392662A2 (en) 2007-04-23 2011-12-07 Basf Se Plant produtivity enhancement by combining chemical agents with transgenic modifications
WO2009040397A1 (en) 2007-09-26 2009-04-02 Basf Se Ternary fungicidal compositions comprising boscalid and chlorothalonil
US20090191138A1 (en) * 2008-01-30 2009-07-30 Mediquest Therapeutics, Inc. Novel topical formulations for improving the appearance of nails
WO2010127878A3 (en) * 2009-05-08 2011-02-03 Sygnis Bioscience Gmbh & Co. Kg Use of thiabendazole and derivatives thereof for the theraphy of neurological conditions
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
WO2011026796A1 (en) 2009-09-01 2011-03-10 Basf Se Synergistic fungicidal mixtures comprising lactylates and method for combating phytopathogenic fungi
WO2012084670A1 (en) 2010-12-20 2012-06-28 Basf Se Pesticidal active mixtures comprising pyrazole compounds
EP2481284A2 (en) 2011-01-27 2012-08-01 Basf Se Pesticidal mixtures
WO2012127009A1 (en) 2011-03-23 2012-09-27 Basf Se Compositions containing polymeric, ionic compounds comprising imidazolium groups
EP3378313A1 (en) 2011-03-23 2018-09-26 Basf Se Compositions containing polymeric, ionic compounds comprising imidazolium groups
WO2013030338A2 (en) 2011-09-02 2013-03-07 Basf Se Agricultural mixtures comprising arylquinazolinone compounds
CN102388909A (en) * 2011-10-13 2012-03-28 光华化学股份有限公司 Complex pesticide composition containing oxine-copper and thiabendazole
EP3300602A1 (en) 2012-06-20 2018-04-04 Basf Se Pesticidal mixtures comprising a pyrazole compound
WO2013189801A1 (en) 2012-06-20 2013-12-27 Basf Se Pyrazole compound and pesticidal mixtures comprising a pyrazole compound
EP3646731A1 (en) 2012-06-20 2020-05-06 Basf Se Pesticidal mixtures comprising a pyrazole compound
WO2014056780A1 (en) 2012-10-12 2014-04-17 Basf Se A method for combating phytopathogenic harmful microbes on cultivated plants or plant propagation material
WO2014095994A1 (en) 2012-12-20 2014-06-26 Basf Se Compositions comprising a triazole compound
EP3498098A1 (en) 2012-12-20 2019-06-19 BASF Agro B.V. Compositions comprising a triazole compound
EP2783569A1 (en) 2013-03-28 2014-10-01 Basf Se Compositions comprising a triazole compound
EP2835052A1 (en) 2013-08-07 2015-02-11 Basf Se Fungicidal mixtures comprising pyrimidine fungicides
WO2015036058A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
EP2979549A1 (en) 2014-07-31 2016-02-03 Basf Se Method for improving the health of a plant
US10899932B2 (en) 2014-10-24 2021-01-26 Basf Se Non-amphoteric, quaternisable and water-soluble polymers for modifying the surface charge of solid particles
WO2017001252A1 (en) 2015-07-02 2017-01-05 BASF Agro B.V. Pesticidal compositions comprising a triazole compound

Also Published As

Publication number Publication date
CH423789A (en) 1966-11-15
CH423791A (en) 1966-11-15
US3055907A (en) 1962-09-25
CH423790A (en) 1966-11-15
BE599143A (en)
MY6500075A (en) 1965-12-31
CY309A (en) 1965-02-18
FR1423609A (en) 1966-01-07
SE310883B (en) 1969-05-19
SE320977B (en) 1970-02-23
CH423793A (en) 1966-11-15
GB948635A (en) 1964-02-05
OA00999A (en) 1968-08-07
DK107167C (en) 1967-05-01
DE1235321B (en) 1967-03-02
ES263822A1 (en) 1961-05-16
CH423792A (en) 1966-11-15

Similar Documents

Publication Publication Date Title
US3017415A (en) Certain benzimidazoles carrying thiazolyl, thiadiazolyl and isothiazolyl substituents in the 2 position
NO138422B (en) PROCEDURE AND SYSTEM FOR CALCINATION OF POWDERED MATERIAL CONTAINING LIME
US3274209A (en) Certain 6-substituted-imidazo[2, 1-b] thiazole compounds
FR2643903A1 (en) NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS
US3897432A (en) Substituted benzimidazole derivatives
EP0174717B1 (en) Benzimidazoles, and their production formulation and use as gastric acid secretion inhibitors
US3401173A (en) Heterocyclic acylaminobenzimidazoles
SU828967A3 (en) Method of preparing guanidine derivatives or their acid-additive salts or their complexes with inorganic metal salts
US4150028A (en) Antiviral thiazolinyl benzimidazoles
DE3884007T2 (en) Arylpiperazinylalkylenephenyl heterocyclic compounds.
US4018790A (en) Substituted 1-sulfonylbenzimidazoles
US3759938A (en) Thiazolidine derivatives
US3336192A (en) Anthelmintic substituted benzimidazole compositions
US4118573A (en) Substituted 1-sulfonylbenzimidazoles
US3274208A (en) Processes for preparing 2-thiazolylbenzimidazole compounds
US5082943A (en) Novel imidazole derivatives
US3468888A (en) 2-substituted pyrimido(1,2-a) benzimidazoles
PL101396B1 (en) METHOD OF PRODUCTION OF 2-CARBOALCOXYAMINOBENZIMIDAZOLYL-5/6 / -SULPHONIC ACID PHENYL ESTERS
NO118911B (en)
KR820002280B1 (en) Process for preapring bengimidazoles
US3183239A (en) 5-ether and 5-thioether-2-heterocyclic benzimidazoles
US3326753A (en) Benzimidazole anthelmintic compositions and method of use
US3357884A (en) Anthelmintic compositions containing benzimidazole derivatives
US3455948A (en) 2-aminobenzimidazole and a process for preparing 2-aminobenzimidazoles
US3338784A (en) Benzimidazole anthelmintic compositions andmethods